Dyne Therapeutics to Present at Investor Conferences in November

Rhea-AI Summary

Dyne Therapeutics, a clinical-stage company focused on muscle disease treatment, will present at several key investor conferences in November 2022. These include the Credit Suisse 31st Annual Healthcare Conference on November 9, Jefferies London Healthcare Conference and Stifel 2022 Healthcare Conference on November 16, and the Piper Sandler 34th Annual Healthcare Conference on November 29. Live webcasts of these presentations will be available on Dyne's investor website for 90 days.

WALTHAM, Mass., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that management is scheduled to present at the following investor conferences in November:

• Credit Suisse 31^st Annual Healthcare Conference, presentation on November 9, 2022 at 11:00 a.m. PT (2:00 p.m. ET) in Rancho Palos Verdes, CA
• Jefferies London Healthcare Conference, fireside chat on November 16, 2022 at 12:20 p.m. GMT (7:20 a.m. ET) in London
• Stifel 2022 Healthcare Conference, fireside chat on November 16, 2022 at 11:30 a.m. ET in New York
• Piper Sandler 34^th Annual Healthcare Conference, fireside chat on November 29, 2022 at 11:00 a.m. ET in New York

A live webcast of each presentation will be available in the Investors & Media section of Dyne’s website at https://investors.dyne-tx.com/news-and-events/events-and-presentations and a replay will be accessible for 90 days.

About Dyne Therapeutics

Dyne Therapeutics is a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases. With its proprietary FORCE™ platform, Dyne is developing modern oligonucleotide therapeutics that are designed to overcome limitations in delivery to muscle tissue seen with other approaches. Dyne has a broad portfolio of programs for serious muscle diseases, including candidates for myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD) and facioscapulohumeral muscular dystrophy (FSHD). For more information, please visit https://www.dyne-tx.com/, and follow us on Twitter, LinkedIn and Facebook.

Contact:

Dyne Therapeutics
Amy Reilly
areilly@dyne-tx.com
857-341-1203

FAQ

What conferences will Dyne Therapeutics participate in November 2022?

Dyne Therapeutics will present at the Credit Suisse 31st Annual Healthcare Conference on November 9, Jefferies London Healthcare Conference and Stifel 2022 Healthcare Conference on November 16, and Piper Sandler 34th Annual Healthcare Conference on November 29.

What time will Dyne present at the Credit Suisse conference?

Dyne will present at the Credit Suisse 31st Annual Healthcare Conference on November 9, 2022, at 11:00 a.m. PT (2:00 p.m. ET).

Where can I watch Dyne Therapeutics' investor presentations?

Live webcasts of Dyne Therapeutics' investor presentations will be available on their investor website, with replays accessible for 90 days.

What is the focus of Dyne Therapeutics?

Dyne Therapeutics focuses on developing innovative therapeutics for genetically driven muscle diseases.

How can I contact Dyne Therapeutics for investor inquiries?

For inquiries, you can contact Amy Reilly at Dyne Therapeutics via email at areilly@dyne-tx.com.